Local nasal immunotherapy: Efficacy of dermatophagoides farinae-chitosan vaccine in murine asthma

International Archives of Allergy and Immunology

Volumn 150, Issue 3, 2009, Pages 221-228

  Liu, Zhigang ^a,c   Guo, Hua ^a,b   Wu, Yiaojiong ^a   Yu, Haiqiong ^a,c   Yang, Haitao ^a   Li, Jing ^a  

^a Shenzhen University School of Medicine   (China)

^b NANCHANG UNIVERSITY   (Thailand)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Asthma; Dermatophagoides farinae chitosan nano vaccine; Intranasal immunotherapy

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; CHITOSAN; DERMATOPHAGOIDES FARINAE VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DRUG EFFICACY; DRUG MECHANISM; EOSINOPHIL; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MOUSE; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BIOCOMPATIBLE MATERIALS; CHITOSAN; DERMATOPHAGOIDES FARINAE; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; MICE; MICE, INBRED BALB C; NANOSPHERES; VACCINES;

EID: 66149103652     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000222674     Document Type: Article

References (24)

1. Kanceljak-Macan B: Current views on allergic disease (in Croatian). Arh Hig Rada Toksikol 2004; 55: 123-134.
2. Vargas MH, Diaz-Mejia GS, Furuya ME, et al: Trends of asthma in Mexico: an 11-year analysis in a nationwide institution. Chest 2004; 125: 1993-1997.
3. Milian E, Diaz-Mejia AM: Allergy to house dust mites and asthma. PR Health Sci J 2004; 23: 47-57.
4. Cole Johnson C, Ownby DR, Havstad SL, et al: Family history, dust mite exposure in early childhood, and risk for pediatric atopy and asthma. J Allergy Clin Immunol 2004; 114: 105-110.
5. Li J, Liu Z, Wu Y, Wu H, Ran P: Chitosan microparticles loaded with mite group 2 allergen Der f 2 alleviate asthma in mice. J Investig Allergol Clin Immunol 2008; 18: 454-460.
6. Jabbal-Gill I, Fischer AN, Rappuoli R, Davis SS, Illum L: Stimulation of mucosal and systemic responses against Bordetella pertussis flamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 1998; 16: 2039-2046.
7. Georgitis JW, Clayton WF, Wypych JI, Barde SH, Reisman RE: Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts. J Allergy Clin Immunol 1984; 74: 694-700.
8. Nickelsen JA, Goldstein S, Mueller U, Wypych JI, Reisman RE, Arbesman CE: Local intranasal immunotherapy for ragweed allergic rhinitis. II. Immunologic response. J Allergy Clin Immunol 1981; 68: 41-45. (Pubitemid 11079116)
9. Nickelsen JA, Georgitis JW, Mueller UR, Kane J, Wypych JI, Goldstein S, Reisman RE, Arbesman CE: Local intranasal immunotherapy for ragweed-allergic rhinitis: a second year of treatment. Clin Allergy 1983; 13: 509-519.
10. Welsh PW, Butterfield JH, Yunginger JW, Agarwal MK, Gleich GJ: Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. J Allergy Clin Immunol 1983; 71: 454-460.
11. Bjorksten B: Local immunotherapy is not documented for clinical use. Allergy 1994; 49: 299-301.
12. Georgitis JW, Nickelsen JA, Wypych JI, Kane JH, Reisman RE: Local nasal immunotherapy: efficacy of low dose aqueous extract. J Allergy Clin Immunol 1985; 75: 496-500.
13. Bertoni M, Cosmi F, Bianchi I, Di Berardino L: Clinical efficacy and tolerability of a steady dosage schedule of local nasal immunotherapy: results of preseasonal treatment in grass pollen rhinitis. Ann Allergy Asthma Immunol 1999; 82: 47-51.
14. Calvo P, Remunan-Lopez C, Vila-Jato JL, et al: Novel hydrophilic chitosan-polythylene oxide microparticle as protein carriers. J Appl Polym Sci 1997; 63: 125-132.
15. Kim J, McKinley L, Siddiqui J, et al: Prevention and reversal of pulmonary inflammation and airway hyperresponsiveness by dexamethasone treatment in a murine model of asthma induced by house dust. Am J Physiol Lung Cell Mol Physiol 2004; 287: L503-L509.
16. Chiang DJ, Ye YL, Chen WL, et al: Ribavirin or CpG DNA sequence-modulated dentic cells decrease the IgE level and airway inflammation. Am J Respir Crit Care Med 2003; 168: 575-580.
17. Annesi-Maesano I: Asthma epidemiology (in French). Rev Prat 2005; 55: 1295-1298.
18. Senti G, Johansen P, Martinez Gomez J, et al: Efficacy and safety of allergen-specific immunotherapy in rhinitis, rhinoconjunctivitis, and bee/wasp venom allergies. Int Rev Immunol 2005; 24: 519-531.
19. Akdis M, Blaser K, Akdis CA: T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005; 116: 961-968; quiz 969.
20. Gieni RS, Yang X, Hayglass KT: Allergenspecific modulation of cytokine synthesis patterns and IgE responses in vivo with chemically modified allergen. J Immunol 1993; 150: 302-310. (Pubitemid 23069806)
21. Gambineri E, Torgerson T, Ochs H: Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003; 15: 430-435.
22. Oh JW, Seroogy CM, Meyer EH, Akbari O, Berry G, Fathman CG, DeKruyff RH, Umetsu DT: CD4 T-helper cells engineered to produce IL-10 reverse allergen-induced airway hyperreactivity and inflammation. J Allergy Clin Immunol 2002; 110: 460-468.
23. Stampfli MR, Cwiartka M, Gajewska BU, Alvarez D, Ritz SA, Inman MD, Xing Z, Jordana M: Interleukin-10 gene transfer to the airway regulates allergic mucosal sensitization in mice. Am J Respir Cell Mol Biol 1999; 21: 586-596. (Pubitemid 129586594)
24. Akbari O, Stock P, DeKruyff RH, et al: Role of regulatory T cells in allergy and asthma. Curr Opin Immunol 2003; 15: 627-633.